- The bioMérieux Share
- Regulated Information
- Shareholder area
bioMérieux fully mobilized against COVID-19 epidemic
Organic growth of 20.8% in the first quarter
Sustained by a sharp sales increase for molecular biology product lines, driven by exceptional demand for respiratory tests. Negative impact expected from the slowdown in routine laboratory business, but only minor effects observed so far. 2020 objectives withdrawn due to a lack of visibility on all the consequences of the global health crisis.